[go: up one dir, main page]

AR008176A1 - ORAL DOSAGE FORM OF CONTROLLED RELEASE AND USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES - Google Patents

ORAL DOSAGE FORM OF CONTROLLED RELEASE AND USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES

Info

Publication number
AR008176A1
AR008176A1 ARP970104130A ARP970104130A AR008176A1 AR 008176 A1 AR008176 A1 AR 008176A1 AR P970104130 A ARP970104130 A AR P970104130A AR P970104130 A ARP970104130 A AR P970104130A AR 008176 A1 AR008176 A1 AR 008176A1
Authority
AR
Argentina
Prior art keywords
medicines
manufacture
dosage form
oral dosage
same
Prior art date
Application number
ARP970104130A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of AR008176A1 publication Critical patent/AR008176A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Una forma de dosificación oral de liberación controlada, que contiene el monohidrocloruro de [R-(Z)]-alfa-(metoxiimino) -alfa-(1-azabiciclo[2.2.2] oct-3-il)acetonitrilo (compuesto X), su base original o cualquier otra de sus sales farmacéuticamente aceptables, y su uso para la fabricación de medicamentos.A controlled-release oral dosage form, containing [R- (Z)] - alpha- (methoxyimino) -alpha- (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile monohydrochloride (compound X) , its original base or any other of its pharmaceutically acceptable salts, and its use for the manufacture of medicines.

ARP970104130A 1996-09-12 1997-09-10 ORAL DOSAGE FORM OF CONTROLLED RELEASE AND USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES AR008176A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition

Publications (1)

Publication Number Publication Date
AR008176A1 true AR008176A1 (en) 1999-12-09

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104130A AR008176A1 (en) 1996-09-12 1997-09-10 ORAL DOSAGE FORM OF CONTROLLED RELEASE AND USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES

Country Status (22)

Country Link
EP (1) EP0929301A2 (en)
JP (1) JP2001500150A (en)
KR (1) KR20000036039A (en)
CN (2) CN1235544A (en)
AR (1) AR008176A1 (en)
AU (1) AU724086B2 (en)
BR (1) BR9711734A (en)
CA (1) CA2265661A1 (en)
CO (1) CO5031291A1 (en)
CZ (1) CZ83299A3 (en)
GB (1) GB9619074D0 (en)
HU (1) HUP9904401A3 (en)
ID (1) ID19589A (en)
IL (1) IL128781A0 (en)
MA (1) MA24359A1 (en)
NO (1) NO991194L (en)
NZ (1) NZ334268A (en)
PE (1) PE2499A1 (en)
PL (1) PL332074A1 (en)
TR (1) TR199900505T2 (en)
WO (1) WO1998010762A2 (en)
ZA (1) ZA978133B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (en) * 1998-03-04 2001-04-20 Gattefosse Ets Sa ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE
NZ505807A (en) * 1998-03-11 2003-01-31 Smithkline Beecham Corp Controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride; useful for the treatment or prophylaxis of dementia
DE19918325A1 (en) * 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
FR2796840B1 (en) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques LOW-DOSE TABLETS AND METHOD OF PREPARATION
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
AR040682A1 (en) 2002-07-25 2005-04-13 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
US20060252820A1 (en) * 2003-04-25 2006-11-09 Tetsuya Suzuki Composition for oral administration containing alkylene dioxybenzene derivative
DE602004002405T3 (en) * 2003-05-14 2013-06-20 Aptalis Pharma Limited CONTROLLED MEDICATION RELEASE COMPOSITION WITH IN VIVO MECHANICAL RESISTANCE
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (en) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk Method for producing solid preparation
JP4785847B2 (en) 2004-08-13 2011-10-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tablet formulation with extended release comprising pramipexole or a pharmaceutically acceptable salt thereof, process for its production and use thereof
NZ553645A (en) * 2004-08-13 2010-09-30 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (en) * 1995-07-29 1998-11-04 Smithkline Beecham Plc PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME.

Also Published As

Publication number Publication date
WO1998010762A2 (en) 1998-03-19
PL332074A1 (en) 1999-08-30
ID19589A (en) 1998-07-23
TR199900505T2 (en) 1999-06-21
HUP9904401A2 (en) 2000-06-28
IL128781A0 (en) 2000-01-31
BR9711734A (en) 1999-08-24
CZ83299A3 (en) 1999-08-11
ZA978133B (en) 1999-04-12
CO5031291A1 (en) 2001-04-27
WO1998010762A3 (en) 1998-06-04
HUP9904401A3 (en) 2001-03-28
CA2265661A1 (en) 1998-03-19
MA24359A1 (en) 1998-07-01
GB9619074D0 (en) 1996-10-23
AU4128897A (en) 1998-04-02
JP2001500150A (en) 2001-01-09
CN1446535A (en) 2003-10-08
NO991194D0 (en) 1999-03-11
PE2499A1 (en) 1999-03-24
NZ334268A (en) 2000-10-27
EP0929301A2 (en) 1999-07-21
KR20000036039A (en) 2000-06-26
AU724086B2 (en) 2000-09-14
NO991194L (en) 1999-03-11
CN1235544A (en) 1999-11-17

Similar Documents

Publication Publication Date Title
AR008176A1 (en) ORAL DOSAGE FORM OF CONTROLLED RELEASE AND USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES
ATE200981T1 (en) MEDICINAL PREPARATION CONTAINING AMOXYCILLIN AND POTASSIUM CLAVUNALATE
ES2191682T3 (en) NEW PHARMACEUTICAL FORMULATION.
DE69514087D1 (en) PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS
ATE312602T1 (en) EXTENDED-RELEASE ORAL PHARMACEUTICAL DOSAGE FORM
SE9102072L (en) ORAL, FIXED, PHARMACEUTICAL dosage form with controlled release
AR027162A1 (en) COMPOUNDS OF 2-PHENYL-3-PHENOXYL-PHENYLTIO-BENZOTIOFEN, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IL110014A0 (en) Solid controlled-release oral dosage forms
PL341055A1 (en) Novel form of a drug for oral administration of active compounds being unstable in acid environments
NO308107B1 (en) Unsolvated crystalline compound, pharmaceutical formulation containing it and use of the compound for the preparation of a pharmaceutical agent
RS50485B (en) Therapeutic combinations comprising amlodipin and atorvastatin
ATA129892A (en) PHARMACEUTICAL COMPOSITION
EE04578B1 (en) Pharmaceutical composition for oral administration of the N-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates
EP0497258A3 (en) Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer
IS3878A (en) Imidazodiazepines compounds, their preparation and use as drugs
PT1077703E (en) FORMS OF ORAL MEDICINES WITH REPRODUCTIVE RELEASE OF THE ACTIVE SUBSTANCE GATIFLOXACIN OR ITS PHARMACEUTICALLY ACCEPTANT SALTS OR HYDRATES
ATE222243T1 (en) PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS
NO934196D0 (en) N, N-disubstituted arylcycloalkylamines, their salts, drugs containing these compounds, their use and process for their preparation
IT1301968B1 (en) ERYTHROMYCIN DERIVATIVES FOR ANTIBIOTIC ACTIVITY
ES2062137T3 (en) USE OF 5'-DEOXI-5'-METHYL-THIOADENOSINE, S-ADENOSYLMETIONINE AND ITS SALTS FOR THE PREPARATION OF REDUCING PHARMACEUTICAL COMPOSITIONS OF SEBORRHEA.
BR9814127A (en) New oral dosage form for carvedilol
EE9400296A (en) Piperidinylthioindole derivatives, dosage forms, active analgesic, methods for their preparation
DK0469440T3 (en) Solid oral dosage forms containing as active ingredient ifosamide
AR002191A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALCANOL COMPOUNDS IN THE FORM OF SOLUTION, PROCEDURE FOR ITS PREPARATION
NO940844D0 (en) Pharmaceutically active hydroxycarboxylic acid derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal